Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on UroGen Pharma (NASDAQ: URGN), saying today's FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE